ESC 365 - CVD prevention and event reduction.

Open Access

CVD prevention and event reduction.

Session: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention

Topic: Atherosclerosis

Speaker: Professor M. Sabatine (Boston, US)

Sponsored by Amgen GmbH.

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Marc Sabatine

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

25 presentations

1 follower

4 more presentations in this session

Introduction - PCSK9 inhibitors: the next chapter in CVD prevention.

Future perspectives in lipid lowering and CVD prevention.

Speaker: Professor P. Sever (London, GB)

Panel discussion - PCSK9 inhibitors: the next chapter in CVD prevention.

Speaker: Professor J. Chapman (Paris, FR)

Close - PCSK9 inhibitors: the next chapter in CVD prevention.

Speaker: Professor J. Chapman (Paris, FR)

Access the full session

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention

Speakers: Professor M. Sabatine, Professor P. Sever, Professor J. Chapman, Professor J. Chapman

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources